HLS Therapeutics Inc (HLS) Stock Statistics & Valuation Metrics

HLS Therapeutics Inc has a market cap or net worth of CAD 128.38M. The enterprise value is CAD 177.89M.

Market Cap

CAD 128.38M

Enterprise Value

CAD 177.89M

HLS Therapeutics Inc has 30,935,060 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

30,935,060

Owned by Insiders

0.11%

Owned by Institutions

1.65%

HLS Therapeutics Inc’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -3.48%.

Return on Equity (ROE)

-0.21

Return on Assets (ROA)

-0.09

Return on Invested Capital (ROIC)

-3.48%

Return on Capital Employed (ROCE)

-0.04

Revenue Per Employee

664.37K

Profits Per Employee

-148.80K

Employee Count

85

Asset Turnover

0.41

Inventory Turnover

4.00

The current PE Ratio of HLS Therapeutics Inc is -12.04. HLS Therapeutics Inc’s PEG ratio is -0.20.

PE Ratio

-12.04

PS Ratio

1.76

PB Ratio

1.97

Price to FCF

5.58

Price to Operating Cash Flow

6.01

PEG Ratio

-0.20

In the last 12 months, HLS Therapeutics Inc had revenue of 56.47M and earned -12.65M in profits. Earnings per share was -0.40.

Revenue

56.47M

Gross Profit

24.01M

Operating Income

―

Pretax Income

-13.10M

Net Income

-12.65M

EBITDA

18.02M

Earnings Per Share (EPS)

-0.40

In the last 12 months, operating cash flow was 18.13M and capital expenditures -695,453, giving a free cash flow of 17.43M billion.

Operating Cash Flow

18.13M

Free Cash Flow

17.43M

Free Cash Flow per Share

0.52

HLS Therapeutics Inc pays an annual dividend of CAD 0.05, resulting in a dividend yield of ―

Dividend Per Share

CAD 0.05

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

20.99%

Earnings Yield

-9.22%

Beta

0.59

52-Week Price Change

-20.64%

50-Day Moving Average

4.10

200-Day Moving Average

4.29

Relative Strength Index (RSI)

46.84

Average Volume (3m)

72.95K

HLS Therapeutics Inc upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 12, 2026

Next Earnings Date

Mar 18, 2027

Ex-Dividend Date

Apr 27, 2023

HLS Therapeutics Inc as a current ratio of 1.11, with Debt / Equity ratio of 80.79%

Current Ratio

1.11

Quick Ratio

0.80

Debt to Market Cap

0.44

Net Debt to EBITDA

2.11

Interest Coverage Ratio

-0.58

In the past 12 months, HLS Therapeutics Inc has paid -452.79K in taxes.

Income Tax

-452.79K

Effective Tax Rate

0.03

HLS Therapeutics Inc EV to EBITDA ratio is 6.14, with an EV/FCF ratio of 6.35.

EV to Sales

2.00

EV to EBITDA

6.14

EV to Free Cash Flow

6.35

EV to Operating Cash Flow

6.22

HLS Therapeutics Inc has CAD 13.71M in cash and marketable securities with CAD 41.84M in debt, giving a net cash position of -CAD 28.13M billion.

Cash & Marketable Securities

CAD 13.71M

Total Debt

CAD 41.84M

Net Cash

-CAD 28.13M

Net Cash Per Share

-CAD 0.91

Tangible Book Value Per Share

-CAD 1.28

Gross margin is 61.41%, with operating margin of -7.95%, and net profit margin of -15.20%.

Gross Margin

61.41%

Operating Margin

-7.95%

Pretax Margin

-16.37%

Net Profit Margin

-15.20%

EBITDA Margin

32.60%

EBIT Margin

-6.56%

The average price target for HLS Therapeutics Inc is CAD 8.23, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

CAD 8.23

Price Target Upside

96.30% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

-1.18%

EPS Growth Forecast

42.93%

Smart Score

7

AI Score

59